

FOR IMMEDIATE RELEASE

Cristal Therapeutics Signs Non-Exclusive License of CliCr® Bioconjugation Platform with Sapreme Technologies

Maastricht, The Netherlands – 09 September 2025, Cristal Therapeutics, a biotech company developing innovative conjugation technologies, today announced it has entered into a non-exclusive license agreement with Sapreme Technologies. The agreement allows Sapreme Technologies to leverage the versatile and highly efficient CliCr® platform in the development of next-generation therapeutics based on their endosomal escape technology.

The CliCr® bioconjugation platform offers a powerful and scalable solution for efficient, site-specific and stable conjugation of biomolecules. Under the terms of the agreement, Cristal Therapeutics grants Sapreme Technologies a non-exclusive license to apply CliCr® across their research and development programs.

Dr. Marco Timmers, CEO of Sapreme Technologies, stated:

"Integrating CliCr® into Sapreme's therapeutics based on our endosomal escape technology, allows us to accelerate our pipeline with a robust manufacturing strategy. We value Cristal Therapeutics' deep expertise in the field and look forward to exploring the full potential of this innovative bioconjugation technology."

Dr. Werner Cautreels, CEO of Cristal Therapeutics, commented:

"We are pleased to collaborate with Sapreme Technologies, a promising biotech with a strong commitment to next-generation therapeutics. This license deal is a validation of the growing interest in our CliCr® platform, which continues to demonstrate broad applicability and robust performance in drug development."

The financial terms of the agreement were not disclosed.

- End -

Media Contact:

Cristianne Rijcken, Chief Science Officer

Cristal Therapeutics B.V.

Email: cristianne.rijcken@cristaltherapeutics.com

Phone: +31 6 24 55 91 75

About Cristal Therapeutics and CliCr®

Cristal Therapeutics is a biotechnology company dedicated to the development of superior bioconjugates with improved therapeutic profiles for better treatment outcomes in patients. The company's proprietary CliCr® (copper free click chemistry for conjugation) platform enables site-specific, rapid, and robust conjugation of a wide variety of biomolecules. Designed to operate under mild up to even extreme conditions, CliCr® offers superior performance for applications in antibody-drug conjugates (ADCs), targeted delivery systems, diagnostics, and more. With unmatched precision, compatibility and ease of manufacturing, CliCr® sets the new standard in bioconjugation. The application of CliCr® significantly improves products by reducing impurities and increasing biological performance. Aimed outcomes include higher efficacy because of prolonged circulation, and better patient safety due to more stable conjugates.